New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 2, 2014
13:25 EDTILMN, ILMN, ILMN, LMNX, LMNX, LMNX, CPHD, CPHD, CPHD, GNMK, GNMK, GNMK, NSTG, NSTG, NSTG, MYGN, MYGN, MYGN, FLDM, FLDM, FLDM, PACB, PACB, PACB, TMO, TMO, TMO, QGEN, QGEN, QGENLeerink's life science tools analyst holds an analyst/industry conference call
Life Science Tools Analyst Leonard discusses the use of nextgen sequencing in a clinical context, early applications and uptake, the merits, demerits of various nextgen sequencing instruments and where new offerings fit on an Analyst/Industry conference call. Relevant companies ILMN, TMO, PACB, FLDM, MYGN, NSTG, GNMK, CPHD, LMNX and QGEN may be discussed on the Analyst/Industry conference call to be held on April 3 at 2 pm.
News For ILMN;TMO;PACB;FLDM;MYGN;NSTG;GNMK;CPHD;LMNX;QGEN From The Last 14 Days
Check below for free stories on ILMN;TMO;PACB;FLDM;MYGN;NSTG;GNMK;CPHD;LMNX;QGEN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 29, 2014
09:27 EDTCPHDCepheid management to meet with Oppenheimer
Meeting to be held in Boston on September 5 hosted by Oppenheimer.
06:21 EDTNSTGNanoString files $100M mixed securities shelf
August 28, 2014
11:53 EDTPACBPacific Biosciences management to meet with Maxim
Subscribe for More Information
09:16 EDTPACBPacific Biosciences milestone payment shows Roche commitment, says Maxim
Maxim believes Roche's (RHHBY) milestone payment to Pacific Biosciences (PACB) indicates that the larger partner is committed to continuing the in vitro diagnostics program despite its recent acquisition and strategic investment with others. Maxim raised its 2014 revenue estimate for Pacific Biosciences to reflect the payment and recommends investors buy shares.
09:01 EDTPACBPacific Biosciences discloses achievement of development milestone
Subscribe for More Information
August 27, 2014
09:04 EDTNSTGNanoString announces unexpected death of Chief Medical Officer
Subscribe for More Information
August 25, 2014
10:11 EDTNSTGNanoString management to meet with Piper Jaffray
Subscribe for More Information
August 22, 2014
10:01 EDTNSTGOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Bio-Techne (TECH) initiated with an Overweight at Stephens... Culp (CFI) initiated with a Buy at Stifel... MobileIron (MOBL) initiated with an Outperform at Imperial Capital... NanoString (NSTG) management to meet with Piper Jaffray... SuperCom (SPCB) initiated with an Outperform at Imperial Capital.
06:06 EDTNSTGNanoString management to meet with Piper Jaffray
Meeting to be held in San Diego on August 26 hosted by Piper Jaffray.
05:45 EDTLMNXLuminex management to meet with Stephens
Subscribe for More Information
August 21, 2014
05:42 EDTILMNIllumina announces strategic partnership with AstraZeneca, Sanofi, Janssen
Illumina (ILMN) announced it has formed collaborative partnerships with leading pharmaceutical companies to develop a universal next-generation sequencing, or NGS,-based oncology test system. The system will be used for clinical trials of targeted cancer therapies with a goal of developing and commercializing a multi-gene panel for therapeutic selection, resulting in a more comprehensive tool for precision medicine. Initial strategic partners include AstraZeneca (AZN), Janssen Biotech, a Johnson & Johnson (JNJ) company, and Sanofi (SNY). Illumina is working with the strategic partners to develop assays that detect and measure multiple variants simultaneously to support partners’ clinical trials, with the objectives of securing regulatory agency approvals and test commercialization. In parallel, Illumina is working with key thought leaders to set standards for NGS-based assays in routine clinical oncology practice, as well as to define regulatory frameworks to enable this new testing paradigm. Together, Illumina and its strategic partners aim to transition from single-analyte companion diagnostics to panel-based assays that select for “companion therapeutics.”
August 20, 2014
10:04 EDTILMNOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
07:18 EDTILMNIllumina upgraded to Outperform from Neutral at Wedbush
Subscribe for More Information
August 19, 2014
11:32 EDTILMNLabCorp prenatal test a negative for Sequenom, says Maxim
Maxim views LabCorp's (LH) announcement today that it will begin offering the informaSeq prenatal test as a long-term negative for Sequenom (SQNM) due to increased competition. The news is also negative for Illumina (ILMN) and PerkinElmer (PKI), who both offer Non-Invasive Prenatal Tests, Maxim adds. The firm recommends buying shares of LabCorp and keeps a Buy rating on the name with a $130 price target.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use